Merrimack to Divest Assets to Ipsen

01.09.17

Skadden is advising Merrimack Pharmaceuticals, Inc. on the sale of cancer treatment drugs ONIVYDE and generic DOXIL to Ipsen S.A. in an asset sale valued at up to $1.025 billion.

Search all news

Archive